Skip to content
PeptidesEncyclopedia
Informational, not medical advice

This is an approved / prescription medicine. Do not use without a prescription and medical supervision.

EMA-approvedaka Regular insulin, Humulin, Novolin

Insulin human — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Insulin human (also known as Regular insulin) is a peptide catalogued under Hormones & Metabolic (Insulin). It is described as: Insulin receptor agonist. Documented context: Diabetes mellitus. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Insulin human?

Human insulin refers to recombinant insulin identical to the endogenous human hormone, supplied as short-acting regular insulin (for example Humulin R, Novolin R) and intermediate-acting NPH; recombinant human insulin was the first genetically engineered human therapeutic.

It is approved worldwide, including by the US FDA and the EMA, and remains foundational, widely-used and comparatively low-cost diabetes therapy.

Evidence level is very high: decades of randomised controlled trials and Cochrane systematic reviews compare regular human insulin against rapid-acting analogues.

How does Insulin human work?

Regular human insulin activates the insulin receptor to stimulate glucose uptake into muscle and fat and to suppress hepatic glucose output, lowering blood glucose.

Injected subcutaneously it self-associates into hexamers, giving a slower onset and longer duration than rapid-acting analogues, so it is dosed some time before meals.

What does the research say about Insulin human?

  • A Cochrane systematic review found only a small HbA1c difference between short-acting insulin analogues and regular human insulin, so regular human insulin remains an effective mealtime option. [1]
  • A meta-analysis showed rapid-acting analogues modestly improved postprandial glucose and reduced hypoglycaemia versus regular human insulin, while overall control was broadly comparable. [2]
  • Recombinant human insulin was the first genetically engineered human therapeutic and established the foundation of all modern insulin therapy. [3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

  • [1] Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus — Siebenhofer A et al., Cochrane Database of Systematic Reviews 2004. (Cochrane systematic review)
  • [2] Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis — Melo KFS et al., Diabetology and Metabolic Syndrome 2019. (Systematic review and meta-analysis)
  • [3] Evolution of insulin development: focus on key parameters — Tibaldi JM et al., Advances in Therapy 2012. (Narrative review)
  • [4] Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus — Rossetti P et al., Archives of Physiology and Biochemistry 2008. (Review)
  • [5] Insulin for the treatment of women with gestational diabetes — Brown J et al., Cochrane Database of Systematic Reviews 2017. (Cochrane systematic review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In practice regular human insulin is injected subcutaneously roughly 30 minutes before meals, while NPH provides intermediate basal coverage, both titrated to glucose targets.

All dosing is individualised and set by a prescribing clinician; this entry gives context only and is not dosing guidance.

Side effects & safety profile

Hypoglycaemia is the central and potentially severe or fatal risk; because regular human insulin acts more slowly and lasts longer than rapid-acting analogues, its peak can be mistimed relative to meals, contributing to late post-meal or nocturnal lows.

Weight gain and injection-site reactions are common, and dosing errors are dangerous because insulin products are not interchangeable unit-for-unit.

Different insulins and concentrations (for example U-100 vs U-500) carry distinct action profiles, so substitutions require clinician oversight.

Stacking & combinations

Regular or NPH human insulin is commonly combined into basal-bolus or premixed regimens and used alongside oral glucose-lowering agents under clinician supervision.

Finding Insulin human vendors

Finding Insulin human vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Sign in to review

Frequently asked questions

It is recombinant insulin identical to the natural human hormone, available as short-acting regular insulin (Humulin R, Novolin R) and intermediate-acting NPH.

References

  1. [1] Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus — Siebenhofer A et al., Cochrane Database of Systematic Reviews 2004. PMID: 15495047. View sourceStudy: Cochrane systematic reviewFound only a minor HbA1c advantage for short-acting analogues over regular human insulin, questioning routine superiority.
  2. [2] Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis — Melo KFS et al., Diabetology and Metabolic Syndrome 2019. PMID: 30622653. View sourceStudy: Systematic review and meta-analysisRapid-acting analogues improved postprandial glucose and reduced hypoglycaemia versus regular human insulin in type 1 diabetes.
  3. [3] Evolution of insulin development: focus on key parameters — Tibaldi JM et al., Advances in Therapy 2012. PMID: 22843207. View sourceStudy: Narrative reviewReviews how recombinant human insulin and later analogues evolved, framing human insulin as the therapeutic foundation.
  4. [4] Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus — Rossetti P et al., Archives of Physiology and Biochemistry 2008. PMID: 18465353. View sourceStudy: ReviewSummarises pharmacokinetic advantages of analogues while acknowledging human insulin's continued clinical role.
  5. [5] Insulin for the treatment of women with gestational diabetes — Brown J et al., Cochrane Database of Systematic Reviews 2017. PMID: 29103210. View sourceStudy: Cochrane systematic reviewEvaluated insulin, including human insulin, as a mainstay pharmacological option in gestational diabetes.
This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.